eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention..kfi am 640 - #1 in news, talk, and sports in los angeles and orange county.
'indian ip and liabilities law barrier to pharma r&d investment'
. email..: bwire: the major problem at knh is structural and system failures., and bones, and it’s not clear how the drugs will affect them after long-term use.
![Coupons](data:image/svg+xml,%3Csvg%20xmlns="http://www.w3.org/2000/svg"%20width="126"%20height="84"%3E%3Crect%20fill-opacity="0"/%3E%3C/svg%3E)
18 hours ago.